Physician profile
Rani V Bui
NPI 1679347843
$1,460.97
in general payments reported to CMS, 2019-2025
10 companies · $1,024 in 2025
The $1,024 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $437 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,392 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,391.98 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $531.46 | 2024-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $244.23 | 2025 | Dupixent |
| Janssen Biotech, INC. | $176.93 | 2024-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $158.01 | 2024-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $125.00 | 2025 | Cabtreo |
| Ucb, INC. | $99.25 | 2025 | Bimzelx |
| Abbvie INC. | $64.31 | 2025 | |
| Lilly USA, LLC | $24.55 | 2025 | Taltz, Ebglyss |
| Incyte Corporation | $19.23 | 2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $18.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rani Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.